Last 12 months
Inside the activity.
7 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 7 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2020 Filed Dec 4, 2020 22:46 UTC |
Pilnik Richard D.Director
|
PurchaseVoting Common Shares, no par value per share | 5,000 | $5.24 | $26,200.00 |
DisclosureSEC source: 0001790300-20-000011 · primary_doc.xml · nonDerivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,846 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 10,168 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| December 04, 2020 Filed Dec 4, 2020 22:46 UTC |
Pilnik Richard D.Director
|
PurchaseVoting Common Shares, no par value per share | 5,000 | $5.50 | $27,497.00 |
DisclosureSEC source: 0001790300-20-000011 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,846 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 10,168 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| November 20, 2020 Filed Nov 23, 2020 21:22 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 15,000 | $4.26 | $63,912.00 |
DisclosureSEC source: 0001235802-20-000138 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,588 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.249 to $4.283, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 7,784 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 36,498 voting common shares held by Michael Giuffre and his wife jointly and 60,160 voting common shares held by Michael Giuffre individually. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 13:16 UTC |
Kellen ScottCFO and Secretary
|
PurchaseVoting Common Shares, no par value per share | 2,000 | $4.19 | $8,386.60 |
DisclosureSEC source: 0001235802-20-000122 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,290 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.1824 to $4.21, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:28 UTC |
Kellen ScottCFO and Secretary
|
GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000054 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 35,000 shares Expires 2030-05-31 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments commencing on September 1, 2020. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:36 UTC |
Gilman Sydney A.VP, Regulatory Affairs
|
GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000055 · primary_doc.xml · derivative · entry 2 Gilman Sydney A. · CIK 0001793016 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Shares · 17,500 shares Expires 2030-05-31 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments commencing on September 1, 2020. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:19 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000053 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Shares · 56,000 shares Expires 2030-05-31 F2 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments commencing on September 1, 2020. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:10 UTC |
ALCORN HARRY W JRChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000052 · primary_doc.xml · derivative · entry 2 ALCORN HARRY W JR · CIK 0001186761 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 35,000 shares Expires 2030-05-31 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments commencing on September 1, 2020. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:59 UTC |
Giuffre Randall MichaelDirector
|
GrantStock Option (right to buy) · Derivative | 13,306 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000051 · primary_doc.xml · derivative · entry 5 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,306 Underlying: Common Shares · 13,306 shares Expires 2030-05-31 F4 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:59 UTC |
Giuffre Randall MichaelDirector
|
GrantVoting Common Shares, no par value per share | 7,784 | $4.59 | $35,728.56 |
DisclosureSEC source: 0001235802-20-000051 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,588 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $35,729. F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 36,498 voting common shares held by Michael Giuffre and his wife jointly and 45,160 voting common shares held by Michael Giuffre individually. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:49 UTC |
Parsons James T.Director
|
GrantStock Option (right to buy) · Derivative | 13,306 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000050 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,306 Underlying: Common Shares · 13,306 shares Expires 2030-05-31 F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:49 UTC |
Parsons James T.Director
|
GrantVoting Common Shares, no par value per share | 8,102 | $4.59 | $37,188.18 |
DisclosureSEC source: 0001235802-20-000050 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,202 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $37,188. F2 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:33 UTC |
Pilnik Richard D.Director
|
GrantStock Option (right to buy) · Derivative | 19,220 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000049 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,220 Underlying: Common Shares · 19,220 shares Expires 2030-05-31 F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 20:33 UTC |
Pilnik Richard D.Director
|
GrantVoting Common Shares, no par value per share | 10,168 | $4.59 | $46,671.12 |
DisclosureSEC source: 0001235802-20-000049 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,846 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $46,667. F2 · balance_after: Includes 7,588 shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:13 UTC |
Gilman Sydney A.VP, Regulatory Affairs
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001235802-19-000131 · primary_doc.xml · derivative · entry 2 Gilman Sydney A. · CIK 0001793016 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-10-31 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments over three years. Read SEC document |
| August 19, 2019 Filed Aug 19, 2019 20:24 UTC |
Kellen ScottCFO and Secretary
|
PurchaseVoting Common Shares, no par value per share | 3,000 | $2.43 | $7,290.00 |
DisclosureSEC source: 0001235802-19-000108 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,290 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.41 to $2.45, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 20:35 UTC |
ALCORN HARRY W JRChief Medical Officer
|
PurchaseVoting Common Shares, no par value per share | 7,260 | $2.67 | $19,365.32 |
DisclosureSEC source: 0001235802-19-000106 · primary_doc.xml · nonDerivative · entry 1 ALCORN HARRY W JR · CIK 0001186761 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,260 Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 20:31 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
PurchaseVoting Common Shares, no par value per share | 1,000 | $2.68 | $2,676.90 |
DisclosureSEC source: 0001235802-19-000105 · primary_doc.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,804 F1 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 10:45 UTC |
Pilnik Richard D.Director
|
PurchaseVoting Common Shares, no par value per share | 7,840 | $2.56 | $20,039.04 |
DisclosureSEC source: 0001235802-19-000107 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,678 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.5387 to $2.5775, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:30 UTC |
Kellen ScottCFO and Secretary
|
GrantStock Option (right to buy) · Derivative | 99,750 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000062 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,750 Underlying: Common Shares · 99,750 shares Expires 2029-06-23 F1 · derivative.exercise_date: Vests in eight nearly equal quarterly installments over two years. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 21:01 UTC |
Xiao ZhenyuDirector
|
GrantStock Option (right to buy) · Derivative | 12,950 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000067 · primary_doc.xml · derivative · entry 3 Xiao Zhenyu · CIK 0001760743 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,950 Underlying: Common Shares · 12,950 shares Expires 2029-06-23 F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:54 UTC |
Verdoorn Todd A.Chief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 71,025 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000066 · primary_doc.xml · derivative · entry 2 Verdoorn Todd A. · CIK 0001759883 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,025 Underlying: Common Shares · 71,025 shares Expires 2029-06-23 F1 · derivative.exercise_date: Vests in eight nearly equal quarterly installments over two years. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:48 UTC |
Pilnik Richard D.Director
|
GrantStock Option (right to buy) · Derivative | 18,700 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000065 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Shares · 18,700 shares Expires 2029-06-23 F2 · derivative.exercise_date: Vests in four equal quarterly installments over one year. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:42 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 264,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000064 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,000 Underlying: Common Shares · 264,000 shares Expires 2029-06-23 F2 · derivative.exercise_date: Vests in eight equal quarterly installments over two years. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:36 UTC |
Parsons James T.Director
|
GrantStock Option (right to buy) · Derivative | 12,950 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000063 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,950 Underlying: Common Shares · 12,950 shares Expires 2029-06-23 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:24 UTC |
Giuffre Randall MichaelDirector
|
GrantStock Option (right to buy) · Derivative | 12,950 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000061 · primary_doc.xml · derivative · entry 5 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,950 Underlying: Common Shares · 12,950 shares Expires 2029-06-23 F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:12 UTC |
ALCORN HARRY W JRChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001235802-19-000060 · primary_doc.xml · derivative · entry 2 ALCORN HARRY W JR · CIK 0001186761 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2029-06-23 F1 · derivative.exercise_date: Vests in eight equal quarterly installments over two years. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:11 UTC |
Pilnik Richard D.Director
|
PurchaseVoting Common Shares, no par value per share | 19,000 | $2.80 | $53,200.00 |
DisclosureSEC source: 0001235802-19-000045 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,838 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.74 to $2.80, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| May 24, 2019 Filed May 28, 2019 11:17 UTC |
Kellen ScottCFO and Secretary
|
PurchaseVoting Common Shares, no par value per share | 4,000 | $2.94 | $11,770.00 |
DisclosureSEC source: 0001235802-19-000044 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,290 Read SEC document |
| March 28, 2019 Filed Mar 29, 2019 20:15 UTC |
ALCORN HARRY W JRChief Medical Officer
|
GiftVoting Common Shares, no par value per share | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-19-000030 · primary_doc.xml · nonDerivative · entry 2 ALCORN HARRY W JR · CIK 0001186761 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 20:15 UTC |
ALCORN HARRY W JRChief Medical Officer
|
PurchaseVoting Common Shares, no par value per share | 150 | $4.46 | $668.39 |
DisclosureSEC source: 0001235802-19-000030 · primary_doc.xml · nonDerivative · entry 1 ALCORN HARRY W JR · CIK 0001186761 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:22 UTC |
Kellen ScottCFO and Secretary
|
PurchaseVoting Common Shares, no par value per share | 1,250 | $4.00 | $5,000.00 |
DisclosureSEC source: 0001235802-18-000180 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,290 Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:48 UTC |
Xiao ZhenyuDirector · 10% owner
|
PurchaseVoting Common Shares, no par value per share | 3,250 | $4.00 | $13,000.00 |
DisclosureSEC source: 0001235802-18-000185 · primary_doc.xml · nonDerivative · entry 1 Xiao Zhenyu · CIK 0001760743 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,100 F1 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:42 UTC |
Verdoorn Todd A.Chief Scientific Officer
|
PurchaseVoting Common Shares, no par value per share | 1,000 | $4.00 | $4,000.00 |
DisclosureSEC source: 0001235802-18-000184 · primary_doc.xml · nonDerivative · entry 1 Verdoorn Todd A. · CIK 0001759883 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:37 UTC |
Pilnik Richard D.Director
|
PurchaseVoting Common Shares, no par value per share | 6,250 | $4.00 | $25,000.00 |
DisclosureSEC source: 0001235802-18-000183 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,838 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:31 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
PurchaseVoting Common Shares, no par value per share | 5,000 | $4.00 | $20,000.00 |
DisclosureSEC source: 0001235802-18-000182 · primary_doc.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,804 F1 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:27 UTC |
Parsons James T.Director
|
PurchaseVoting Common Shares, no par value per share | 2,250 | $4.00 | $9,000.00 |
DisclosureSEC source: 0001235802-18-000181 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 F1 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:17 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 11,250 | $4.00 | $45,000.00 |
DisclosureSEC source: 0001235802-18-000179 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,804 F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 36,498 voting common shares held by Michael Giuffre and his wife jointly and 45,160 voting common shares held by Michael Giuffre individually. Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 21:08 UTC |
ALCORN HARRY W JRChief Medical Officer
|
PurchaseVoting Common Shares, no par value per share | 1,000 | $4.00 | $4,000.00 |
DisclosureSEC source: 0001235802-18-000178 · primary_doc.xml · nonDerivative · entry 1 ALCORN HARRY W JR · CIK 0001186761 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.